Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK1 | P06493 | 18/20 | 1.00 |
| ▸ | CDK5 | Q00535 | 13/20 | 1.00 |
| ▸ | CDK2 | P24941 | 11/20 | 0.80 |
| ▸ | CDK7 | P50613 | 8/20 | 0.80 |
| ▸ | CCNE1 | P24864 | 6/20 | 0.80 |
| ▸ | CCNB1 | P14635 | 6/20 | 0.80 |
| ▸ | CDK4 | P11802 | 5/20 | 0.80 |
| ▸ | CCND1 | P24385 | 5/20 | 0.80 |
| ▸ | CCNH | P51946 | 5/20 | 0.80 |
| ▸ | CDK9 | P50750 | 4/20 | 0.80 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.80 |
| ▸ | CSNK1D | P48730 | 3/20 | 0.80 |
| ▸ | CLK2 | P49760 | 3/20 | 0.80 |
| ▸ | DYRK1A | Q13627 | 3/20 | 0.80 |
| ▸ | CLK4 | Q9HAZ1 | 3/20 | 0.80 |
| ▸ | CSNK1G2 | P78368 | 2/20 | 0.80 |
| ▸ | CSNK1G1 | Q9HCP0 | 2/20 | 0.80 |
| ▸ | HIPK4 | Q8NE63 | 2/20 | 0.80 |
| ▸ | SRPK1 | Q96SB4 | 2/20 | 0.80 |
| ▸ | CCNB2 | O95067 | 2/20 | 0.80 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2097192 | 1.00 | CDK1 (1.00) | CDK1CDK5CDK2CDK7CCNE1 | |
| SCHEMBL1216848 | 1.00 | CDK1 (1.00) | CDK1CDK5CDK2CDK7CCNE1 | |
| SCHEMBL21726198 | 0.90 | CDK1 (0.81) | CDK1CDK5CDK2CDK7CCNE1 | |
| SCHEMBL1218376 | 0.90 | CDK1 (1.00) | CDK1CDK5CDK2CDK7CCNE1 | |
| SCHEMBL2098033 | 0.90 | CDK1 (1.00) | CDK1CDK5CDK2CDK7CCNE1 | |
| SCHEMBL4286629 | 0.90 | CDK1 (1.00) | CDK1CDK5CDK2CDK7CCNE1 | |
| Seliciclib SCHEMBL94728 | 0.89 | CDK1 (1.00) | CDK1CDK5CDK2CDK7CCNE1 | |
| (S)-Roscovitine SCHEMBL2907488 | 0.89 | CDK1 (1.00) | CDK1CDK5CDK2CDK7CCNE1 | |
| SCHEMBL4276454 | 0.89 | CDK1 (1.00) | CDK1CDK5CDK2CDK7CCNE1 | |
| SCHEMBL17004030 | 0.89 | CDK1 (0.80) | CDK1CDK5CDK2CDK7CCNE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140249165-A1 | PURINE DERIVATIVES FOR TREATMENT OF CYSTIC DISEASES | GENZYME CORPORATION (US) | 2014-09-04 | — | — | US | claimed |
| EP-2617423-A1 | Purine derivatives for the treatment of cystic diseases | GENZYME CORPORATION (US) | 2013-07-24 | — | — | EP | claimed |
| US-20110046164-A1 | Purine Derivatives for Treatment of Cystic Diseases | GENZYME CORPORATION | 2011-02-24 | — | — | US | claimed |
| US-20100273802-A1 | NEW PURINE DERIVATIVES HAVING, IN PARTICULAR, ANTI-PROLIFERATIVE PROPERTIES, AND THEIR BIOLOGICAL USES | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIGUE (C.N.R.S.) | 2010-10-28 | — | — | US | claimed |
| EP-2076268-A1 | PURINE DERIVATIVES FOR THE TREATMENT OF CYSTIC DISEASES | Genzyme Corporation (US) | 2009-07-08 | — | — | EP | claimed |
| WO-2008051502-A1 | PURINE DERIVATIVES FOR THE TREATMENT OF CYSTIC DISEASES | GENZYME CORPORATION (US) | 2008-05-02 | — | — | WO | claimed |
| US-20030186999-A1 | Purine derivatives having, in particular, antiproliferative properties, and their biological uses | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIGUE (C.N.R.S.) | 2003-10-02 | — | — | US | claimed |
| EP-1308447-A1 | Purine derivatives having antiproliferative properties and biological uses thereof | Centre National de la Recherche Scientifique (C.N.R.S.) (FR) | 2003-05-07 | — | — | EP | claimed |
| US-20020049218-A1 | Purine derivatives having, in particular, antiproliferative properties, and their biological uses | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIGUE (C.N.R.S.) | 2002-04-25 | — | — | US | claimed |
| EP-0874847-A1 | NOVEL PURINE DERIVATIVES HAVING, IN PARTICULAR, ANTIPROLIFERATIVE PROPERTIES, AND BIOLOGICAL USES THEREOF | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 1998-11-04 | — | — | EP | claimed |
| WO-1997020842-A1 | NOVEL PURINE DERIVATIVES HAVING, IN PARTICULAR, ANTIPROLIFERATIVE PROPERTIES, AND BIOLOGICAL USES THEREOF | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N.R.S.) (FR) | 1997-06-12 | — | — | WO | claimed |
| US-20140249165-A1 | PURINE DERIVATIVES FOR TREATMENT OF CYSTIC DISEASES | GENZYME CORPORATION (US) | 2014-09-04 | — | — | US | disclosed |
| EP-2617423-A1 | Purine derivatives for the treatment of cystic diseases | GENZYME CORPORATION (US) | 2013-07-24 | — | — | EP | disclosed |
| US-8163762-B2 | Purine derivatives having, in particular, anti-proliferative properties, and their biological uses | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2012-04-24 | — | — | US | disclosed |
| US-20110046164-A1 | Purine Derivatives for Treatment of Cystic Diseases | GENZYME CORPORATION | 2011-02-24 | — | — | US | disclosed |
| US-20030186999-A1 | Purine derivatives having, in particular, antiproliferative properties, and their biological uses | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIGUE (C.N.R.S.) | 2003-10-02 | — | — | US | disclosed |
| EP-1308447-A1 | Purine derivatives having antiproliferative properties and biological uses thereof | Centre National de la Recherche Scientifique (C.N.R.S.) (FR) | 2003-05-07 | — | — | EP | disclosed |
| EP-0874847-B1 | NOVEL PURINE DERIVATIVES HAVING, IN PARTICULAR, ANTIPROLIFERATIVE PROPERTIES, AND BIOLOGICAL USES THEREOF | CENTRE NAT RECH SCIENT (FR) | 2003-03-19 | — | — | EP | disclosed |
| US-20020049218-A1 | Purine derivatives having, in particular, antiproliferative properties, and their biological uses | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIGUE (C.N.R.S.) | 2002-04-25 | — | — | US | disclosed |
| US-6316456-B1 | Purine derivatives having, in particular, antiproliferative properties, and their biological uses | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2001-11-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110046164-A1 | Purine Derivatives for Treatment of Cystic Diseases | TYMP, PKD1, CFTR | CDK1 20/4885CDK5 54/4885CDK2 52/4885 |
| US-20100273802-A1 | NEW PURINE DERIVATIVES HAVING, IN PARTICULAR, ANTI-PROLIFERATIVE PROPERTIES, AND THEIR BIOLOGICAL USES | PNP, TYMP, DPYD | CDK1 404/4885CDK5 324/4885CDK2 226/4885 |
| US-20030186999-A1 | Purine derivatives having, in particular, antiproliferative properties, and their biological uses | PNP, TYMP, NUDT1 | CDK1 501/4885CDK5 517/4885CDK2 359/4885 |
| US-20020049218-A1 | Purine derivatives having, in particular, antiproliferative properties, and their biological uses | PNP, TYMP, NUDT1 | CDK1 501/4885CDK5 517/4885CDK2 359/4885 |
| US-20140249165-A1 | PURINE DERIVATIVES FOR TREATMENT OF CYSTIC DISEASES | TYMP, PKD1, CFTR | CDK1 20/4885CDK5 54/4885CDK2 52/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.